Saving Appropriate Content Sample Clauses

Saving Appropriate Content. The content saved in the Google Drive folder should be specific to education. Material deemed “unnecessary” for education could result in disciplinary action. Files stored in Google Drive or laptop are not private and are subject to viewing and approval by district authorities.
Sample 1Sample 2Sample 3See All (12)
AutoNDA by SimpleDocs
Saving Appropriate Content. The content saved in the student folders should be specific to education. The space provided by the District File Server is limited and there will be a quota of appropriate space allowed for each user. Material deemed “unnecessary” for education that is saved to this location will deteriorate school resources, complicate backups, and could slow down the school’s network performance. Files stored in the student folders are not private and are subject to viewing and approval by district authorities.
Sample 1Sample 2
Saving Appropriate Content. The content saved in the Documents folder should be specific to education. The space provided by the District File Server is limited and there will be a quota of appropriate space allowed for each user. Material deemed “unnecessary” for education that is saved to this location will deteriorate school resources, complicate backups, and could slow down the school’s network performance. Files not saved in the Documents folder on the tablet/laptop will not be backed up by the school and will be lost in the event that the computer is re-imaged. Files stored on the tablet/laptop are not private and are subject to viewing and approval by district authorities.
Sample 1
Saving Appropriate Content. The content saved in the Google Drive folder should be specific to education. Material deemed ³XQQHFHVVDU\´co uldIreRsuUlt in HdisGciXpliFnarDy WactLioRn. QFi les stored in Google Drive or laptop are not private and are subject to viewing and approval by district authorities.
Sample 1

Related to Saving Appropriate Content

  • Appropriate Safeguards BA shall implement appropriate safeguards to prevent the use or disclosure of Protected Information other than as permitted by the Contract or Addendum, including, but not limited to, administrative, physical and technical safeguards in accordance with the Security Rule, including, but not limited to, 45 C.F.R. Sections 164.308, 164.310, and 164.312. [45 C.F.R. Section 164.504(e)(2)(ii)(B); 45 C.F.R. Section 164.308(b)]. BA shall comply with the policies and procedures and documentation requirements of the Security rule, including, but not limited to, 45 C.F.R. Section 164.316 [42 U.S.C. Section 17931].

  • Appropriate Use It will use its Project property for appropriate purposes (including joint development purposes as well as uses that provide program income to support public transportation) for the duration of the useful life of its Project property, which may extend beyond the duration of the Award, and consistent with other requirements FTA may impose.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!